Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Atara Biotherapeutics registered direct offering
The stock is listed on Nasdaq
CytomX Therapeutics $100 million stock offering
The stock is listed on the Nasdaq Global Select Market
Auna $62.1 million senior secured notes offering
We advised Auna on the offering
Biogen $1.75 billion senior notes offering
The investment-grade notes are due 2031, 2035 and 2055
Haleon $3.1 billion secondary placing of ordinary shares
The private placement included 617,553,920 ordinary shares
Owens & Minor $1 billion secured notes offering
The high-yield notes are due 2030
Insulet $419 million repurchases of convertible senior notes
We advised the agent on the transaction
Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Insulet $450 million senior notes offering
The high-yield notes are due 2033
Integer Holdings $1 billion convertible senior notes offering
The 1.875% convertible senior notes are due 2030